

*PATENT*  
*Attorney Docket No. P04885US1*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	YIP, et al.	Group Art Unit:	1631
SERIAL NO:	09/744,628	Examiner:	Zeman, M
FILED:	June 1, 2001	Confirmation No:	3027
TITLE:	IDENTIFICATION OF COMPOUNDS FOR MODULATING DIMERIC RECEPTORS		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING DATE OF EITHER A FINAL ACTION  
OR NOTICE OF ALLOWANCE (37 C.F.R. § 1.97(c))**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This information disclosure statement is being filed *before* the mailing date of either a final action under § 1.113 or a notice of allowance under § 1.311, whichever occurs first.

Attached are Forms PTO/SB/08A and 08B (formerly Form PTO-1449) listing the relevant art known to the applicant herein. Copies of the references are enclosed. The Examiner is requested to consider the references and make them of record.

Applicants disclose herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose. Legible copies of all items listed in Forms PTO/SB/08A

CERTIFICATE OF MAILING/TRANSMISSION (37 CFR 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:


## MAILING

☒ deposited with the United States Postal Service with sufficient postage as First Class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 3/6/04

## FACSIMILE

☐ transmitted by facsimile to the Patent and Trademark Office, Art Unit \_\_\_\_\_ at Fax No. (703) 872-\_\_\_\_\_ 4

No. (703) 872-            
  
HEIDI S. NEBEL

03/24/2004 WARRHAM1 00000084 09744628

180.00 NP

01 FC:1806

Refund Ref: 03/24/2004 WARRHAN1 0000135018

**CHECK Refund Total: \$40.00**


and 08B (formerly Form PTO-1449) accompany this information statement, except those identified above.

Applicant elects the option to pay the fee set forth in 37 C.F.R. sec 1.17(p) for submission of an information disclosure statement under § 1.97(c). A check in the amount of \$220.00 is enclosed.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. (Notice of January 9, 1992, 1135 O.G. 13-25, at 25.)

Respectfully submitted,



HEIDI S. NEBEL, Reg. No. 37,719  
McKEE, VOORHEES & SEASE, P.L.C.  
801 Grand Avenue, Suite 3200  
Des Moines, Iowa 50309-2721  
Phone No. (515) 288-3667  
Fax No. (515) 288-1338  
**CUSTOMER NO: 22885**

- mlw -

Attorneys of Record

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	09/744,628
Filing Date	January 25, 2001
First Named Inventor	YIP, Cecil
Group Art Unit	1631
Examiner Name	ZEMAN, Mary K.
Attorney Docket Number	P04885US1

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner  
Signature**


Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/744,628
Filing Date	January 25, 2001
First Named Inventor	YIP, Cecil
Group Art Unit	1631
Examiner Name	ZEMAN, Mary K.
Attorney Docket Number	P04885US1

Sheet 2 of 2

**OTHER ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		C.C. Yip and P. Ottensmeyer. "Three-dimensional Structural Interactions of Insulin and its Receptor." J. Biol. Chem. 278:27329-27332, 2003.	
		C. Tan et al. "Structure-based de novo design of ligands using a three-dimensional model of the insulin receptor." Bioorganic & Medicinal Chemistry Letters, Vol. 14: 1407-1410, 2004.	
		"Insulin-like growth factor I receptor precursor (CD221 antigen)". P08069. Created: Aug 1, 1988. Sequence updated: Aug 1, 1988. Annotation updated: Mar 15, 2004.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.